Kathleen Borthwick - Feb 10, 2024 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Role
SVP, INTERIM CFO
Signature
/s/ Edgar Cale, Attorney-in-Fact
Stock symbol
PASG
Transactions as of
Feb 10, 2024
Transactions value $
-$1,426
Form type
4
Date filed
2/13/2024, 07:36 PM
Previous filing
Jan 3, 2024
Next filing
Mar 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PASG Common Stock Options Exercise +4K +15.42% 29.9K Feb 10, 2024 Direct F1
transaction PASG Common Stock Sale -$1.43K -1.47K -4.91% $0.97 28.5K Feb 13, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PASG Restricted Stock Unit Options Exercise $0 -4K -33.33% $0.00 8K Feb 10, 2024 Common Stock 4K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
F3 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.